Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$16.01

-0.06 (-0.37%)

, AGN

Allergan

$193.99

2.66 (1.39%)

07:25
12/22/16
12/22
07:25
12/22/16
07:25

Ironwood up 6% after reporting data from linaclotide colonic release trials

Earlier, Ironwood Pharmaceuticals (IRWD) and Allergan plc (AGN) announced topline data from Phase IIb clinical trials evaluating the investigational linaclotide colonic release-1, or CR1, and linaclotide colonic release-2, or CR2, formulations in adult patients with irritable bowel syndrome with constipation.

IRWD

Ironwood

$16.01

-0.06 (-0.37%)

AGN

Allergan

$193.99

2.66 (1.39%)

IRWD Ironwood
$16.01

-0.06 (-0.37%)

04/26/16
JPMS
04/26/16
NO CHANGE
JPMS
Ironwood Linzess safety concerns overblown, says JPMorgan
04/26/16
COWN
04/26/16
NO CHANGE
COWN
Outperform
Ironwood short report does not discuss any new information, says Cowen
Cowen analyst Boris Peaker,commented on the short report on Ironwood (IRWD) issued by Phase Five Research and said it doesn't appear to discuss any new data. Peaker said the analysis ignores the co-morbidities of patients that are on Linzess, which has been in 2M patients, many with significant other illnesses and on multiple other background therapies. Additionally, the report overlooked the acquisition of Zurampic today from AstraZeneca (AZN) that was favorably structured with a $100M upfront payment to Ironwood, the analyst said. Peaker said feedback on Linzess from consultants at Cowen's Healthcare Conference was positive and reiterates his Outperform rating.
04/27/16
UBSW
04/27/16
NO CHANGE
Target $8
UBSW
Sell
Ironwood had no new safety concerns with Linzess, says UBS
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.
12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.
AGN Allergan
$193.99

2.66 (1.39%)

12/09/16
SBSH
12/09/16
NO CHANGE
SBSH
Buy
Citi sees favorable setup for Allergan heading into 2017
After hosting meetings with management, Citi analyst Liav Abraham sees a favorable setup for Allergan shares heading into 2017. The analyst highlights the lowered revenue expectations following the recent Q3 results, ongoing "strong" performance from key franchises as well as pipeline and M&A optionality. Abraham keeps a Buy rating on the shares.
12/15/16
GSCO
12/15/16
DOWNGRADE
GSCO
Buy
Allergan downgraded to Buy from Conviction Buy at Goldman
12/21/16
BERN
12/21/16
NO CHANGE
BERN
Allergan acquisition has positive aspects, says Bernstein
After Allergan agreed to buy LifeCell, analyst Aaron Gal says that LifeCell seems to "merge well" with Allergan's aesthetics business. The analyst thinks that the acquisition should have "a fair number of synergies," while "LifeCell is another long duration asset that is not protected solely via patent protection." The analyst believes that the cost of the deal is "reasonable." He keeps a $275 price target and an Outperform rating on Allergan.

TODAY'S FREE FLY STORIES

OMER

Omeros

$21.29

0.49 (2.36%)

13:22
08/23/17
08/23
13:22
08/23/17
13:22
Periodicals
Omeros 'still won't answer basic questions,' STAT's Feuerstein says »

Omeros' press…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUB

People's Utah Bancorp

$27.00

0.05 (0.19%)

13:20
08/23/17
08/23
13:20
08/23/17
13:20
Hot Stocks
People's Utah Bancorp CEO sells 12,170 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$20.44

0.54 (2.71%)

13:20
08/23/17
08/23
13:20
08/23/17
13:20
Options
Second day of interest in CenturyLink September puts »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

13:17
08/23/17
08/23
13:17
08/23/17
13:17
Hot Stocks
PetMed Express tells Bloomberg Aurelius report 'false and defamatory' »

In response to an earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

$NSD

NASDAQ Market Internals

13:17
08/23/17
08/23
13:17
08/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$118.03

-0.25 (-0.21%)

13:16
08/23/17
08/23
13:16
08/23/17
13:16
Conference/Events
Sempra Energy to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 14

    Sep

$NYE

NYSE Market Internals

13:16
08/23/17
08/23
13:16
08/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/23/17
08/23
13:15
08/23/17
13:15
General news
Jackson Hole outlook: »

Jackson Hole outlook: the…

CAVM

Cavium

$60.98

0.84 (1.40%)

13:15
08/23/17
08/23
13:15
08/23/17
13:15
Conference/Events
Cavium has a conference call hosted by William Blair »

William Blair Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 06

    Sep

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

13:12
08/23/17
08/23
13:12
08/23/17
13:12
Recommendations
PetMed Express analyst commentary  »

PetMed Express recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

SIX

Six Flags

$51.97

-1.25 (-2.35%)

, DIS

Disney

$102.04

-0.73 (-0.71%)

13:06
08/23/17
08/23
13:06
08/23/17
13:06
Hot Stocks
Six Flags Magic Mountain to launch 365-day operation on January 1 »

Six Flags Entertainment…

SIX

Six Flags

$51.97

-1.25 (-2.35%)

DIS

Disney

$102.04

-0.73 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

S

Sprint

$8.29

0.065 (0.79%)

, SSNLF

Samsung

$2,030.00

-70 (-3.33%)

13:05
08/23/17
08/23
13:05
08/23/17
13:05
Hot Stocks
Samsung Galaxy Note8 coming to Sprint for $20 a month »

Sprint (S) announced the…

S

Sprint

$8.29

0.065 (0.79%)

SSNLF

Samsung

$2,030.00

-70 (-3.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

WSM

Williams-Sonoma

$43.04

0.19 (0.44%)

13:05
08/23/17
08/23
13:05
08/23/17
13:05
Options
Williams Sonoma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

MSI

Motorola Solutions

$86.67

0.26 (0.30%)

, ZURVY

Zurich Insurance

$30.34

-0.04 (-0.13%)

13:04
08/23/17
08/23
13:04
08/23/17
13:04
Hot Stocks
Motorola Solutions names Troy Mattern as head of product cybersecurity »

Motorola Solutions (MSI)…

MSI

Motorola Solutions

$86.67

0.26 (0.30%)

ZURVY

Zurich Insurance

$30.34

-0.04 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

HPQ

HP Inc.

$18.91

-0.115 (-0.60%)

, HPE

HP Enterprise

$17.69

0.02 (0.11%)

12:56
08/23/17
08/23
12:56
08/23/17
12:56
Earnings
On The Fly: What to watch in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$18.91

-0.115 (-0.60%)

HPE

HP Enterprise

$17.69

0.02 (0.11%)

LNVGY

Lenovo

$11.13

-0.07 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 05

    Sep

  • 06

    Sep

BABA

Alibaba

$173.90

-0.562 (-0.32%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on Alibaba »

Alibaba mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ON

ON Semiconductor

$16.04

0.29 (1.84%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on ON Semiconductor »

ON Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

KRO

Kronos Worldwide

$19.25

-0.25 (-1.28%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on Kronos Worldwide »

Kronos Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
08/23/17
08/23
12:55
08/23/17
12:55
General news
U.S. VIX equity volatility is up 4% near 11.82 »

U.S. VIX equity…

HCCI

Heritage-Crystal Clean

$18.15

-0.05 (-0.27%)

12:54
08/23/17
08/23
12:54
08/23/17
12:54
Periodicals
Breaking Periodicals news story on Heritage-Crystal Clean »

Heritage-Crystal Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 08

    Sep

  • 09

    Sep

12:50
08/23/17
08/23
12:50
08/23/17
12:50
General news
Breaking General news story  »

Dallas Federal Reserve…

CVM

CEL-SCI

$1.95

-0.341 (-14.89%)

12:47
08/23/17
08/23
12:47
08/23/17
12:47
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI »

Sabby Management reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

12:46
08/23/17
08/23
12:46
08/23/17
12:46
Periodicals
PetMed Express 'exploiting' opioid epidemic in America, Aurelius Value says »

PetMed Express is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

GDDY

GoDaddy

$41.78

-0.09 (-0.21%)

12:41
08/23/17
08/23
12:41
08/23/17
12:41
Recommendations
GoDaddy analyst commentary  »

GoDaddy shares defended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

SPY

SPDR S&P 500 ETF Trust

$244.96

-0.48 (-0.20%)

12:40
08/23/17
08/23
12:40
08/23/17
12:40
Options
Sizable put spreads in SPDR 500 Trust »

Sizable put spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.